Key result
BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia are associated with cardiovascular and metabolic complications, necessitating cardiovascular surveillance and risk factor modification.
This review highlights the importance of cardiovascular surveillance and risk factor modification in CML patients treated with BCR-ABL TKIs due to potential cardiovascular and metabolic toxicities.
No takes yet. Share an insight, caveat, or question.
Growing evidence of TKI CV complications in CML is limited by methodological issues; leaves open definitive risk assessment.
Aghel et al. (2017) conducted a review in Chronic myeloid leukemia (CML). BCR-ABL tyrosine kinase inhibitors (TKIs) was evaluated. BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia are associated with cardiovascular and metabolic complications, necessitating cardiovascular surveillance and risk factor modification.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: